COMP <GO>
BHC vs JNJ // REVENUE GROWTH (YOY)
Bausch Health Companies Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BHC 7
— JNJ 7
▲ REVENUE GROWTH (YOY) LEADER: BHC
LAST: $8.20 (-7.97%) • MKT CAP: $3.33B
revenue-growth
6.70%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BHC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.60% | 25.50% | -17.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.5x | 18.5x | -8.00 | BHC | /valuation <GO> |
| Free Cash Flow Yield | 22.00% | 2.97% | +19.03 | BHC | /fcf-yield <GO> |
| Operating Margin | 17.70% | 34.70% | -17.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 1.50% | 28.50% | -27.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 6.70% | 6.00% | +0.70 | BHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | BHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | BHC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.3 | 60.4 | +11.95 | BHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.08 | -0.11 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.7x | 23.0x | -3.30 | BHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.33B | $662.49B | -$659.16B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BHC REV | JNJ REV | BHC GROSS % | JNJ GROSS % | BHC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.27B | $94.19B | 44.0% | 67.9% | $1.00B | $19.70B |
| FY 2024 | $9.63B | $88.82B | 44.0% | 69.1% | $1.26B | $19.84B |
| FY 2023 | $8.76B | $85.16B | 44.0% | 44.0% | $637.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
JNJ // BETA 1.08